Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting

European Child and Adolescent Psychiatry, Supplement

Volumn 13, Issue 1, 2004, Pages

  Döpfner, Manfred ^a   Gerber, Wolff Dieter ^b   Banaschewski, Tobias ^c   Breuer, Dieter ^a   Freisleder, Franz Joseph ^d   Gerber Von Müller, Gabi ^b   Günter, Michael ^e   Hässler, Frank ^f   Ose, Claudia ^g   Rothenberger, Aribert ^c   Schmeck, Klaus ^h   Sinzig, Judith ^a   Stadler, Christina ^h   Uebel, Henrik ^c   Lehmkuhl, Gerd ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Inst Kinder /Jugendpsychiat/P   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h GOETHE UNIVERSITY   (Germany)

Author keywords

Attention deficit hyperactivity disorder; Children; Extended release methylphenidate; Stimulant

Indexed keywords

MEDIKINET RETARD; METHYLPHENIDATE; PLACEBO; PSYCHOSTIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CHILD; CHILD BEHAVIOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; HYPERACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL; SCORING SYSTEM; SUSTAINED RELEASE PREPARATION; TASK PERFORMANCE; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; METHYLPHENIDATE;

EID: 4444347786     PISSN: 14335719     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00787-004-1009-3     Document Type: Article

References (38)

1. Biedermann J, Lopez FA, Boellner SW, Chandler MC (2002) A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/ hyperactivity disorder. Pediatrics 110: 258-266
2. Birmaher B, Greenhill LL, Cooper TB, Fried J, Maminski B (1989) Sustained released methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 28: 768-772
3. Breuer D, Döpfner M, Heise CA (2004) Reabilität und Validität einer Skala zur Erfassung von Störungen der Aufmerksamkeit und Regelbeachtung im Unterricht (in preparation)
4. Brown GL, Hunt RD, Ebert MH, Bunney WE, Kopin IJ (1979) Plasma levels of d-amphetamine in hyperactive children: serial behavior and motor responses. Psychopharmacology 62:133-140
5. Brühl B, Döpfner M, Lehmkuhl G (2000) Der Fremdbeurteilungsbogen für hyperkinetische Störungen (FBB-HKS) - Prävalenz hyperkinetischer Störungen im Elternurteil und psychometrische Kriterien. Kindheit und Entwicklung 9: 116-126
6. Döpfner M, Banaschewski T, Schmidt J, Uebel, H, Schmeck K, Gerber WD, Günter M, Knölker U, Gehrke M, Häßler F, Möhler E, Brünger M, Ose C, Fischer, R, Poustka F, Lehmkuhl G, Rothenberger A (2003) Langwirksames Methylphenidat bei Kindern mit Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung. Eine multizentrische Studie. Nervenheilkunde 22:85-92
7. Döpfner M, Breuer D, Schürmann S, Wolff Metternich T, Rademacher C, Lehmkuhl G (2004) Effectiveness of an adaptive multimodal treatment in children with Attention Deficit Hyperactivity Disorder - global outcome. European Child & Adolescent Psychiatry 13(Suppl 1):I117-I129
8. nd edn. Huber, Bern
9. Döpfner M, Lehmkuhl G (2002) Evidenzbasierte Therapie von Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS). Praxis der Kinderpsychologie und Kinderpsychiatrie 51:419-440
10. Döpfner M, Deutsche Methylphenidat Gruppe (2004) Wirkdauer und Sicherheit von Methylphenidat-Retard im Vergleich zu einer zweimaligen Gabe von schnell freigesetztem Methylphenidat bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen (in preparation)
11. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998) ADHD Rating Scale IV: Checklists, Norms, and Clinical Interpretation. Guilford Press, New York
12. Greenhill LL (1995) Attention-deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatry Clin North Am 4:123-168
13. Greenhill LL, Findling RL, Swanson JM, MPH MR ADHD Study Group (2002) A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:1-7
14. Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R (1999) The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses. Can J Psychiatry 44:1025-1035
15. Lord J, Paisley S (2000) The clinical effectiveness and cost-effectiveness of methylphenidate for hyperactivity in childhood. National Institute for Clinical Excellence (NICE) version 2, London
16. Lopez F, Silva R, Pestreich L, Muniz R (2003) Comperative Efficacy of two once daily methylphenidate formulations (Ritalin® LA and Concerta®) and placebo in children with Attention Deficit Hyperactivity Disorder across the school day. Pediatr Drugs 5:545-555
17. Lyseng-Williamson KA, Keating GM (2002) Extended-Release Methylphenidate (Ritalin® LA). Drugs 62:2251-2259
18. McBurnett K, Swanson JM, Pfittner LJ, Tamm L (1997) A measure of ADHD-related classroom apairment based on targets for behavioral intervention. J Attention Disord 2:69-76
19. McCracken JT, Biedermann J, Greenhill, LL, Laurence L, Swanson J, McGough J, Spencer TJ, Posner K, Wigal S, Pataki C, Zhang Y, Tulloch S (2003) Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Child Adolesc Psychiatry 42:673-683
20. McGough JJ, Biederman J, Greenhill LL, McCracken JT, Spencer TJ, Posner K, Wigal S, Gornbein J, Tulloch S, Swanson JM (2003) Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 42:684-691
21. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano G, Morisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fiebelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD (2001) Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:1-15
22. Pelham WE, Gnagy EM, Chronis AM, Burrows-Maclean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL (1999) A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three-times-daily methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 104:1300-1311
23. Pelham WE, Karen E, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover, MD, Dahl RE (1990) Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and Pemoline. Pediatrics 86:226-236
24. Pelham WE, Sturges J, Hoza J, Schmidt C, Bijlsma JJ, Milich R, Moorer S (1987) Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 80:491-501
25. Pelham WE, Swanson JM, Bender Furman M, Schwindt H (1995) Pemoline effects on children with ADHD: A time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 34:1504-1513
26. Pelham WE, Wheeler T, Chronis A (1998) Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 27:190-205
27. Schubert I, Köster I, Adam C, Ihle P, Döpfner M, Lehmkuhl G (2003) Psychopharmakaverordnungen bei Kindern und Jugendlichen mit Behandlungsanlass "Hyperkinetische Störung". Zeitschrift für Gesundheitswissenschaften 11:306-324
28. Sherman M, Hertzig ME (1991) Prescribing practices of Ritalin: the Suffolk County, New York study. In: Greenhill LL, Osman BB (eds) Ritalin: Theory and Patient Management. New York, Mary Ann Liebert, pp 187-193
29. Sinzig J, Döpfner M, Plück J, Banaschewski T, Stephani U, Lehmkuhl G, Rothenberger A, Arbeitsgruppe Methylphenidat (2004) Lassen sich hyperkinetische Auffälligkeiten am Nachmittag durch eine Morgengabe von Methylphenidat Retard vermindern? Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie (in press)
30. Sleator EK, Ullmann RK, von Neumann A (1982) How do hyperactive children feel about taking stimulants and will they tell the doctor? Clin Pediatr (Phila) 21:474-479
31. Swanson, JM (1992) School based assessment and interventions for ADD students. KC, Publishing, Irvine
32. Swanson JM, Agler D, Fineberg E, Wigal S, Flynn D, Fineberg K, Quintana Y, Talebi H (2000) University of California, Irvine, Laboratory School Protocol for pharmacokinetic and pharmacodynamic studies. In: Greenhill LL, Osman BB (eds) Ritalin: Theory and Practice. Mary Ann Liebert, New York, pp 405-432
33. Swanson JM, Gupta, S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S (2003) Development of a new once-a-day formulation of methylphenidate for treatment of attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 60:204-211
34. Swanson JM, Gupta S, Williams L, Agler D, Lerner M, Wigal S (2002b) Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 41: 1306-1314
35. Swanson JM, Lerner M, Wigal T, Steinhoff K, Greenhill L, Posner K, Freid J, Wigal S (2002a) The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Attention Disord 6(Suppl 1):S73-S88
36. Swanson JM, Wigal S, Greenhill LL, Browne R, Waslik B, Lerner M, Williams L, Flynn D, Agler D, Crowley K, Fineberg E, Baren M, Cantwell DP (1998) Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 37:519-526
37. Wilens T, Pelham W, Stein M, Conners KC, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M (2003) ADHD treatment with once-daily OROS® methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424-433
38. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G (2001) Randomized, controlled, trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 180: 883-982